N
REGN icon

Natixis’s Regeneron Pharmaceuticals REGN Stock Holding History

Natixis’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-396
Closed -$235K – 1161
2022
Q2 		$235K Buy
+396
New +$257K ﹤0.01% 1010

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Natixis's REGN Position: Q1 2026 in Review

Natixis increased its Regeneron Pharmaceuticals (REGN) stake by 64% in Q1 2026, buying an estimated $16.5M and bringing the position to 55,307 shares worth $42.7M. The position accounts for 0.15% of the portfolio, ranked #94.

Natixis first reported a position in REGN in Q2 2014 and has held it in 33 quarters since. The position peaked at $92.1M in Q1 2022. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Natixis held 55,307 shares of Regeneron Pharmaceuticals worth $42.7M as of Q1 2026.
  • Natixis bought 21,507 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $16.5M.
  • Regeneron Pharmaceuticals made up 0.15% of Natixis's portfolio in Q1 2026, its #94 holding.
  • Natixis first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 33 quarters since.
  • Natixis's Regeneron Pharmaceuticals position peaked at $92.1M in Q1 2022.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.